KPTI

1.15

1.32% +0.015

Dopo l'orario di chiusura: 1.20 0.05 +4.35%

Karyopharm Therapeutics Inc (KPTI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.135

Aprire:

$1.15

Volume 24 ore:

1.56M

Capitalizzazione di mercato:

$135.37M

Reddito:

$146.03M

Utile/perdita netta:

$-143.10M

Rapporto P/E:

-0.8712

EPS:

-1.32

Flusso di cassa netto:

$-92.72M

1 W Prestazione:

+5.50%

1M Prestazione:

-16.67%

6M Prestazione:

+47.44%

1 anno Prestazione:

-53.06%

Intervallo 1D:

$1.125

$1.19

Portata 52W:

$0.6174

$2.67

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Nome

Karyopharm Therapeutics Inc

Settore

Healthcare (1209)

Industria

Biotechnology (699)

Telefono

617-658-0600

Indirizzo

85 Wells Avenue, 2nd Floor, Newton, MA

Dipendente

154

Cinguettio

@Karyopharm

Prossima data di guadagno

2024-05-29

Ultimi documenti SEC

KPTI's Discussions on Twitter

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-01-19	Iniziato	Piper Sandler	Overweight
2022-11-04	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2022-02-09	Aggiornamento	JP Morgan	Underweight → Neutral
2021-11-19	Ripresa	Morgan Stanley	Equal-Weight
2021-08-06	Downgrade	JP Morgan	Overweight → Neutral
2021-08-06	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-08-06	Downgrade	SVB Leerink	Outperform → Mkt Perform
2020-07-02	Iniziato	Morgan Stanley	Overweight
2020-03-04	Iniziato	Barclays	Overweight
2020-01-17	Downgrade	Wedbush	Outperform → Neutral
2019-07-23	Aggiornamento	JP Morgan	Neutral → Overweight
2019-07-05	Reiterato	H.C. Wainwright	Buy
2019-07-05	Reiterato	Robert W. Baird	Outperform
2019-03-01	Downgrade	JP Morgan	Overweight → Neutral
2019-02-28	Reiterato	BofA/Merrill	Underperform
2019-02-27	Downgrade	BofA/Merrill	Neutral → Underperform
2019-01-03	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-12-03	Iniziato	B. Riley FBR	Buy
2018-11-09	Aggiornamento	Wedbush	Neutral → Outperform
2018-05-24	Downgrade	Wedbush	Outperform → Neutral
2018-04-02	Ripresa	Leerink Partners	Outperform
2017-11-15	Ripresa	H.C. Wainwright	Buy
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2016-09-08	Reiterato	H.C. Wainwright	Buy
2016-08-30	Aggiornamento	Jefferies	Hold → Buy
2016-08-18	Iniziato	H.C. Wainwright	Buy
2016-06-28	Iniziato	Robert W. Baird	Outperform

Mostra tutto

Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie

Selling Buzz: Karyopharm Therapeutics Inc [KPTI] President and CEO Paulson Richard A. sells 3576 shares of the ... - Knox Daily

Knox Daily

UPDATE 2-Karyopharm Therapeutics prices blood cancer treatment after FDA approval - Yahoo Sport Australia

Yahoo Sport Australia

Karyopharm's Refinancing Transactions and Amended Royalty Agreement – Global Legal Chronicle - Global Legal Chronicle

Global Legal Chronicle

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from ... - MarketBeat

MarketBeat

JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - GlobeNewswire

GlobeNewswire

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Defense World

Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari